

## Audit Review Table

Blue Cross and Blue Shield of New Mexico (Org ID: 1825, SubID: 9522, Medicaid, Spec Area: None, Spec Proj: None); Measurement Year - 2014

The Auditor lock has been applied to this submission.

Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
<b>Effectiveness of Care: Prevention and Screening</b>						
<b>Adult BMI Assessment (aba)</b>	Y		N	79.25%	R	Reportable
<b>Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (wcc)</b>	Y		N			
<i>BMI Percentile</i>				55.41%	R	Reportable
<i>Counseling for Nutrition</i>				55.63%	R	Reportable
<i>Counseling for Physical Activity</i>				50.11%	R	Reportable
<b>Childhood Immunization Status (cis)</b>	Y		N			
<i>DTaP</i>				80.57%	R	Reportable
<i>IPV</i>				92.72%	R	Reportable
<i>MMR</i>				90.51%	R	Reportable
<i>HiB</i>				92.94%	R	Reportable
<i>Hepatitis B</i>				92.72%	R	Reportable
<i>VZV</i>				90.07%	R	Reportable
<i>Pneumococcal Conjugate</i>				80.79%	R	Reportable
<i>Hepatitis A</i>				88.52%	R	Reportable
<i>Rotavirus</i>				74.83%	R	Reportable
<i>Influenza</i>				51.43%	R	Reportable
<i>Combination #2</i>				76.82%	R	Reportable
<i>Combination #3</i>				74.39%	R	Reportable
<i>Combination #4</i>				73.07%	R	Reportable
<i>Combination #5</i>				63.36%	R	Reportable
<i>Combination #6</i>				45.70%	R	Reportable
<i>Combination #7</i>				62.69%	R	Reportable
<i>Combination #8</i>				45.70%	R	Reportable
<i>Combination #9</i>				40.40%	R	Reportable
<i>Combination #10</i>				40.40%	R	Reportable
<b>Immunizations for Adolescents (ima)</b>	Y		N			
<i>Meningococcal</i>				39.10%	R	Reportable

<i>Tdap/Td</i>				42.16%	R	Reportable
<i>Combination #1</i>				33.93%	R	Reportable
<b>Human Papillomavirus Vaccine for Female Adolescents (hvp)</b>	Y			9.15%	R	Reportable
<b>Lead Screening in Children (lsc)</b>	Y		N	32.64%	R	Reportable
<b>Breast Cancer Screening (bcs)</b>	Y			51.23%	R	Reportable
<b>Cervical Cancer Screening (ccs)</b>	Y			28.35%	R	Reportable
<b>Non-Recommended Cervical Cancer Screening in Adolescent Females (ncs)</b>	Y			2.42%	R	Reportable
<b>Chlamydia Screening in Women (chl)</b>	Y					
<i>16-20 Years</i>				40.31%	R	Reportable
<i>21-24 Years</i>				46.72%	R	Reportable
<i>Total</i>				43.68%	R	Reportable
<b>Effectiveness of Care: Respiratory Conditions</b>						
<b>Appropriate Testing for Children with Pharyngitis (cwp)</b>	Y	Y		68.09%	R	Reportable
<b>Appropriate Treatment for Children With URI (uri)</b>	Y	Y		88.33%	R	Reportable
<b>Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis (aab)</b>	Y	Y		22.15%	R	Reportable
<b>Use of Spirometry Testing in the Assessment and Diagnosis of COPD (spr)</b>	Y			NA	R	Denominator fewer than 30
<b>Pharmacotherapy Management of COPD Exacerbation (pce)</b>	Y	Y				
<i>Systemic Corticosteroid</i>				32.86%	R	Reportable
<i>Bronchodilator</i>				43.33%	R	Reportable
<b>Use of Appropriate Medications for People With Asthma (asm)</b>	Y	Y				
<i>5-11 Years</i>				91.59%	R	Reportable
<i>12-18 Years</i>				84.85%	R	Reportable
<i>19-50 Years</i>				84.44%	R	Reportable
<i>51-64 Years</i>				NA	R	Denominator fewer than 30

<i>Total</i>				85.48%	R	Reportable
<b>Medication Management for People With Asthma (mma)</b>	Y	Y				
<i>5-11 Years - Medication Compliance 50%</i>				43.88%	R	Reportable
<i>5-11 Years - Medication Compliance 75%</i>				20.41%	R	Reportable
<i>12-18 Years - Medication Compliance 50%</i>				48.21%	R	Reportable
<i>12-18 Years - Medication Compliance 75%</i>				25.00%	R	Reportable
<i>19-50 Years - Medication Compliance 50%</i>				55.26%	R	Reportable
<i>19-50 Years - Medication Compliance 75%</i>				23.68%	R	Reportable
<i>51-64 Years - Medication Compliance 50%</i>				NA	R	Denominator fewer than 30
<i>51-64 Years - Medication Compliance 75%</i>				NA	R	Denominator fewer than 30
<i>Total - Medication Compliance 50%</i>				49.51%	R	Reportable
<i>Total - Medication Compliance 75%</i>				23.79%	R	Reportable
<b>Asthma Medication Ratio (amr)</b>	Y	Y				
<i>5-11 Years</i>				62.50%	R	Reportable
<i>12-18 Years</i>				46.97%	R	Reportable
<i>19-50 Years</i>				55.56%	R	Reportable
<i>51-64 Years</i>				NA	R	Denominator fewer than 30
<i>Total</i>				55.04%	R	Reportable
<b>Effectiveness of Care: Cardiovascular Conditions</b>						
<b>Controlling High Blood Pressure (cbp)</b>	Y			51.66%	R	Reportable
<b>Persistence of Beta-Blocker Treatment After a Heart Attack (pbh)</b>	Y	Y		NA	R	Denominator fewer than 30
<b>Effectiveness of Care: Diabetes</b>						
<b>Comprehensive Diabetes Care (cdc)</b>	Y		N			
<i>Hemoglobin A1c (HbA1c) Testing</i>				83.42%	R	Reportable
<i>HbA1c Poor Control (&gt;9.0%)</i>				47.26%	R	Reportable
<i>HbA1c Control (&lt;8.0%)</i>				43.12%	R	Reportable
<i>HbA1c Control (&lt;7.0%)</i>				NR	NR	Plan chose not to report
<i>Eye Exam (Retinal) Performed</i>				54.23%	R	Reportable
<i>Medical Attention for Nephropathy</i>				78.61%	R	Reportable
<i>Blood Pressure Control (&lt;140/90 mm Hg)</i>				57.38%	R	Reportable
<b>Effectiveness of Care: Musculoskeletal Conditions</b>						

<b>Disease Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis (art)</b>	Y	Y		63.10%	R	Reportable
<b>Use of Imaging Studies for Low Back Pain (lbp)</b>	Y			72.66%	R	Reportable
<b>Effectiveness of Care: Behavioral Health</b>						
<b>Antidepressant Medication Management (amm)</b>	Y	Y				
<i>Effective Acute Phase Treatment</i>				59.97%	R	Reportable
<i>Effective Continuation Phase Treatment</i>				47.77%	R	Reportable
<b>Follow-Up Care for Children Prescribed ADHD Medication (add)</b>	Y	Y				
<i>Initiation Phase</i>				49.26%	R	Reportable
<i>Continuation and Maintenance (C&amp;M) Phase</i>				64.29%	R	Reportable
<b>Follow-Up After Hospitalization for Mental Illness (fuh)</b>	Y	Y				
<i>30-Day Follow-Up</i>				58.49%	R	Reportable
<i>7-Day Follow-Up</i>				39.00%	R	Reportable
<b>Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medication (ssd)</b>	Y	Y		79.65%	R	Reportable
<b>Diabetes Monitoring for People With Diabetes and Schizophrenia (smd)</b>	Y			44.62%	R	Reportable
<b>Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (smc)</b>	Y			NA	R	Denominator fewer than 30
<b>Adherence to Antipsychotic Medications for Individuals With Schizophrenia (saa)</b>	Y	Y		60.00%	R	Reportable
<b>Use of Multiple Concurrent Antipsychotics in Children and Adolescents (apc)</b>	Y	Y				
<i>1-5 Years</i>				NA	R	Denominator fewer than 30
<i>6-11 Years</i>				NA	R	Denominator fewer than 30
<i>12-17 Years</i>				NA	R	Denominator fewer than 30

<i>Total</i>				NA	R	Denominator fewer than 30
<b>Metabolic Monitoring for Children and Adolescents on Antipsychotics (apm)</b>	Y	Y				
<i>1-5 Years</i>				NA	R	Denominator fewer than 30
<i>6-11 Years</i>				27.27%	R	Reportable
<i>12-17 Years</i>				32.79%	R	Reportable
<i>Total</i>				31.03%	R	Reportable
<b>Effectiveness of Care: Medication Management</b>						
<b>Annual Monitoring for Patients on Persistent Medications (mpm)</b>	Y	Y				
<i>ACE Inhibitors or ARBs</i>				85.06%	R	Reportable
<i>Digoxin</i>				NA	R	Denominator fewer than 30
<i>Diuretics</i>				85.16%	R	Reportable
<i>Total</i>				84.96%	R	Reportable
<b>Access/Availability of Care</b>						
<b>Adults' Access to Preventive/Ambulatory Health Services (aap)</b>	Y					
<i>20-44 Years</i>				71.91%	R	Reportable
<i>45-64 Years</i>				82.21%	R	Reportable
<i>65+ Years</i>				85.87%	R	Reportable
<i>Total</i>				76.61%	R	Reportable
<b>Children and Adolescents' Access to Primary Care Practitioners (cap)</b>	Y					
<i>12-24 Months</i>				90.29%	R	Reportable
<i>25 Months - 6 Years</i>				81.34%	R	Reportable
<i>7-11 Years</i>				85.80%	R	Reportable
<i>12-19 Years</i>				85.27%	R	Reportable
<b>Annual Dental Visit (adv)</b>	Y	Y				
<i>2-3 Years</i>				47.84%	R	Reportable
<i>4-6 Years</i>				63.26%	R	Reportable
<i>7-10 Years</i>				66.93%	R	Reportable
<i>11-14 Years</i>				61.38%	R	Reportable
<i>15-18 Years</i>				51.43%	R	Reportable

19-21 Years				29.60%	R	Reportable
Total				57.46%	R	Reportable
<b>Initiation and Engagement of AOD Dependence Treatment (iet)</b>	Y	Y				
Initiation of AOD Treatment: 13-17 Years				51.56%	R	Reportable
Engagement of AOD Treatment: 13-17 Years				25.00%	R	Reportable
Initiation of AOD Treatment: 18+ Years				38.97%	R	Reportable
Engagement of AOD Treatment: 18+ Years				14.24%	R	Reportable
Initiation of AOD Treatment: Total				39.45%	R	Reportable
Engagement of AOD Treatment: Total				14.66%	R	Reportable
<b>Prenatal and Postpartum Care (ppc)</b>	Y					
Timeliness of Prenatal Care				73.08%	R	Reportable
Postpartum Care				54.52%	R	Reportable
<b>Call Answer Timeliness (cat)</b>	Y			89.69%	R	Reportable
<b>Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (app)</b>	Y	Y				
1-5 Years				NA	R	Denominator fewer than 30
6-11 Years				44.44%	R	Reportable
12-17 Years				56.45%	R	Reportable
Total				51.35%	R	Reportable
<b>Utilization</b>						
<b>Frequency of Ongoing Prenatal Care (fpc)</b>	Y					
<21 Percent				16.06%	R	Reportable
21-40 Percent				7.69%	R	Reportable
41-60 Percent				6.56%	R	Reportable
61-80 Percent				14.48%	R	Reportable
81+ Percent				55.20%	R	Reportable
<b>Well-Child Visits in the First 15 Months of Life (w15)</b>	Y		N			
0 Visits				3.62%	R	Reportable
1 Visit				3.62%	R	Reportable
2 Visits				4.92%	R	Reportable
3 Visits				8.26%	R	Reportable
4 Visits				14.29%	R	Reportable
5 Visits				20.96%	R	Reportable

6+ Visits				44.34%	R	Reportable
Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (w34)	Y		N	56.64%	R	Reportable
Adolescent Well-Care Visits (awc)	Y		N	36.29%	R	Reportable
Frequency of Selected Procedures (fsp)	Y				R	Reportable
Ambulatory Care: Total (amba)	Y				R	Reportable
Ambulatory Care: Dual Eligibles (ambb)	Y				R	Reportable
Ambulatory Care: Disabled (ambc)	Y				R	Reportable
Ambulatory Care: Other (ambd)	Y				R	Reportable
Inpatient Utilization--General Hospital/Acute Care: Total (ipua)	Y				R	Reportable
Inpatient Utilization--General Hospital/Acute Care: Dual Eligibles (ipub)	Y				R	Reportable
Inpatient Utilization--General Hospital/Acute Care: Disabled (ipuc)	Y				R	Reportable
Inpatient Utilization--General Hospital/Acute Care: Other (ipud)	Y				R	Reportable
Identification of Alcohol and Other Drug Services: Total (iada)	Y	Y			R	Reportable
Identification of Alcohol and Other Drug Services: Dual Eligibles (iadb)	Y	Y			R	Reportable
Identification of Alcohol and Other Drug Services: Disabled (iadc)	Y	Y			R	Reportable
Identification of Alcohol and Other Drug Services: Other (iadd)	Y	Y			R	Reportable
Mental Health Utilization: Total (mpta)	Y	Y			R	Reportable
Mental Health Utilization: Dual Eligibles (mptb)	Y	Y			R	Reportable
Mental Health Utilization: Disabled (mptc)	Y	Y			R	Reportable
Mental Health Utilization: Other (mptd)	Y	Y			R	Reportable
Antibiotic Utilization: Total (abxa)	Y	Y			R	Reportable
Antibiotic Utilization: Dual Eligibles (abxb)	Y	Y			R	Reportable
Antibiotic Utilization: Disabled (abxc)	Y	Y			R	Reportable
Antibiotic Utilization: Other (abxd)	N	N			NR	Measure Unselected

Relative Resource Use						
Relative Resource Use for People With Diabetes (rdi)	N				NR	Measure Unselected
Relative Resource Use for People With Asthma (ras)	N	N			NR	Measure Unselected
Relative Resource Use for People With Cardiovascular Conditions (rca)	N				NR	Measure Unselected
Relative Resource Use for People With Hypertension (rhy)	N				NR	Measure Unselected
Relative Resource Use for People With COPD (rco)	N				NR	Measure Unselected
Health Plan Descriptive Information						
Board Certification (bcr)	N				NR	Measure Unselected
Total Membership (tlm)	Y				R	Reportable
Enrollment by Product Line: Total (enpa)	Y				R	Reportable
Enrollment by Product Line: Dual Eligibles (enpb)	Y				NR	Plan chose not to report
Enrollment by Product Line: Disabled (enpc)	Y				NR	Plan chose not to report
Enrollment by Product Line: Other (enpd)	Y				NR	Plan chose not to report
Enrollment by State (ebs)	Y				R	Reportable
Race/Ethnicity Diversity of Membership (rdm)	N				NR	Measure Unselected
Language Diversity of Membership (ldm)	N				NR	Measure Unselected
Weeks of Pregnancy at Time of Enrollment (wop)	Y				R	Reportable